In this study, we describe a new mouse model for multiresistant HER2-positive breast cancer with lung metastases and compare the anti-cancer effects of three HER2-targeting ADCs both in vitro and in vivo using the model. This evidence concerns the gene ERBB2 and breast carcinoma.